Alaunos Therapeutics, Inc. (TCRT) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2025.
Company Overview: Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. Following a strategic reprioritization in August 2023, the company discontinued its legacy clinical-stage TCR-T cell therapy oncology programs to focus exclusively on an internally developed, preclinical small-molecule program for obesity and metabolic disorders (lead candidate ALN1003). The company operates with a minimal workforce (one full-time employee as of March 31, 2026) and relies heavily on consultants.
Key Milestone: In March 2026, the company announced positive preclinical proof-of-concept data for ALN1003 in diet-induced obesity (DIO) mouse models, showing dose-dependent weight loss and improved metabolic biomarkers.
Key Financial Metrics
| Metric ($ in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $5 | $10 |
| Net Loss | $(4,176) | $(4,679) |
| Accumulated Deficit | $(924,622) | $(920,446) |
| Cash and Cash Equivalents (Year End) | $1,385 | $1,091 |
| Stockholders' Equity | $2,153 | $2,063 |
| Operating Cash Flow | $(2,869) | $(4,971) |
| Financing Cash Flow | $3,261 | $0 |
Liquidity: As of December 31, 2025, the company held approximately $1.4 million in cash. Management estimates a monthly cash burn rate of approximately $0.28 million, projecting resources to be sufficient only into the second quarter of 2026.
Material Changes vs. Prior Period
- Revenue: Decreased by 50% to $5,000, driven by de minimis royalty revenue from a legacy collaboration (Solasia Pharma).
- Research & Development (R&D): Increased by 277% to $1.36 million (from $0.36 million) due to the expansion of the obesity and metabolic disorders program.
- General & Administrative (G&A): Decreased by 36% to $2.87 million (from $4.46 million) following workforce reductions and cost-saving initiatives.
- Capital Raises: In 2025, the company raised approximately $3.26 million through financing activities, including a registered direct offering and private placements of Series A-1 and Series A-2 Convertible Preferred Stock. No financing occurred in 2024.
- Management Changes: Dale Curtis Hogue, Jr. resigned as CEO and Director in July 2025. Holger Weis was appointed CEO. Michael A. Jerman was appointed to the Board.
Outlook, Risks, and Contingencies
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Current capital resources are insufficient to fund planned operations for at least one year from the issuance date of the financial statements. Additional capital is required to advance the obesity program to IND-enabling studies.
- Nasdaq Compliance: Stockholders' equity of $2.2 million as of December 31, 2025, remains below the Nasdaq Capital Market minimum requirement of $2.5 million. The company is at risk of delisting if it cannot regain compliance within the allowed timeframe.
- Internal Controls: The company identified a material weakness in internal control over financial reporting due to a lack of sufficient personnel to allow for required segregation of duties.
- Development Risks: The obesity program is in early preclinical stages. Success depends on favorable data from additional animal studies, formulation optimization, and securing substantial additional funding. There is no assurance of regulatory approval or commercialization.
- Legacy Obligations: The company entered a settlement agreement with MD Anderson in December 2025 to resolve payment disputes, agreeing to pay $285,000 in installments through May 2026.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and monthly burn rate to confirm the timeline for potential insolvency or need for dilutive financing.
- Nasdaq Status: Monitor for any formal deficiency notices from Nasdaq regarding stockholders' equity and the company's compliance plan.
- Capital Raising: Assess the likelihood and terms of upcoming equity or debt financings required to fund IND-enabling studies.
- Preclinical Data: Review the detailed data for ALN1003, specifically regarding the "behavior-coupled dosing" limitations noted in the filing where weight loss may be confounded by reduced water/food intake.
- Internal Controls: Evaluate the remediation plan for the material weakness in internal controls and the risk of future financial misstatements.